Targeting Aldehyde Dehydrogenase for Cancer Prevention
以醛脱氢酶为靶点预防癌症
基本信息
- 批准号:10369718
- 负责人:
- 金额:$ 60.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-04-15 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:AldehydesAnimalsAntibodiesBiological Response ModifiersCD8-Positive T-LymphocytesCarboxylic AcidsCell LineCell SurvivalCell physiologyCellsCharacteristicsCultured CellsDataDendritic CellsDevelopmentDisease ResistanceDrug CombinationsDrug TargetingDrug resistanceEffector CellEnzymesExhibitsFamily memberFlow CytometryGeneticImmuneImmune responseImmunosuppressionImmunotherapyIndividualIsatinKnock-outLethal Dose 50LinkMalignant NeoplasmsMeasuresMediatingModelingMusNatural Killer CellsNatural ProductsNeoplasm MetastasisPathway interactionsPatientsPharmaceutical PreparationsPharmacotherapyPopulationProcessProtein FamilyProtein IsoformsProteinsRecurrenceRegulatory T-LymphocyteResearchResistanceResistance developmentRoleSignal TransductionT-LymphocyteTestingTherapeuticToxic effectTreatment EfficacyTreatment ProtocolsTretinoinTumor-DerivedTumor-infiltrating immune cellsValidationVertebral columnaldehyde dehydrogenasesanti-PD-1anti-PD1 antibodiesanti-PD1 therapyantibody immunotherapybasecancer cellcancer preventioncancer stem cellcell typechemotherapyclinical translationclinically relevantdrug developmentefficacy testingenzyme activitygenetic approachimmune functionimmunogenic cell deathimprovedinhibitorinnovationmelanomamortalitymouse modelnanoparticleneoplastic cellnovelpre-clinicalpreclinical efficacypreventresponsestem cell biomarkersstem cell populationstem-like celltargeted agenttumortumor microenvironmenttumor-immune system interactions
项目摘要
ABSTRACT:
In cancer, aldehyde dehydrogenase (ALDH) enzyme activity is high in dendritic cells and regulatory T-cells,
hypothesized to modulate the immune response and also in cancer stem cells (CSCs) to aid the development of
recurrent resistant disease. It is therefore surprising that drugs targeting ALDH have not been developed to
modulate these processes in cancer. To investigate this issue, we tested the efficacy of existing isoform-specific
and broad-spectrum ALDH inhibitors on cultured cells and found that none were very effective at modulating cell
survival. Furthermore, we predicted that a broad-spectrum inhibitor would be needed due to the overlapping
functions of the ALDH family members. These observations provided the rationale to develop a non-toxic broad-
spectrum ALDH inhibitor, which would kill ALDH+ CSCs to prevent recurrent resistant disease, and improve
immunotherapy of melanoma. Thus, the central hypothesis is that a non-toxic ALDH inhibitor can be developed
to reduce recurrent resistant disease development mediated by ALDH+ CSCs and improve the efficacy of
existing immunotherapies by reducing immune suppression. Preliminary data show development of a potent
non-toxic ALDH inhibitor built on the backbone of the Isatin natural product. This agent eliminates CSCs with
high ALDH activity, preventing increases in ALDH+ cells typically seen with traditional drug treatments. Finally,
the inhibitor improves the preclinical efficacy of anti-PD1 immunotherapy in a syngeneic mouse melanoma model
where this approach alone is not effective. Based on these hypothesis-supporting preliminary data, the following
Specific Aims are proposed. First, determine how effectively a non-toxic broad-spectrum ALDH inhibitor
eliminates the melanoma ALDH+ CSC population that expands when treating with traditional chemotherapy.
Furthermore, determine its potency when combined with traditional chemotherapy to prevent recurrent resistant
disease development. This will be achieved by isolating ALDH+ and ALDH- cell populations from cell lines and
patient derived (PDX) tumors and determining inhibitor efficacy for preventing recurrent resistant disease
development when provided in combination with current clinically relevant chemotherapy. Finally, the
mechanistic basis for inhibition of resistance by the agent combination will be identified. Second, determine the
efficacy of a non-toxic broad-spectrum ALDH inhibitor on immune regulatory and effector cells in the tumor
microenvironment, alone and when combined with anti-PD1 antibody immunotherapy. Specific targeting of
ALDH in melanoma tumor cells and in host cells on therapeutic efficacy will be tested. Mechanisms leading to
enhanced immune response will be identified by defining the impact of the inhibitor and antibody combinations
on immune cell composition and function within the tumors, assessing the relative ALDH levels in the immune
cell populations, and using transient and genetic approaches to target the modulating immune cells. These
significant discoveries would demonstrate the efficacy of targeting ALDH enzymes in cancer for modulating
resistance and immune cell function, providing needed preclinical validation necessary for clinical translation.
摘要:
在癌症中,醛脱氢酶(ALDH)酶活性在树突细胞和调节性T细胞中很高,
假设调节免疫反应,也在癌症干细胞(CSC)中,以帮助发展
复发性抗性疾病。因此,令人惊讶的是,靶向ALDH的药物尚未被开发出来,
调节癌症中的这些过程。为了研究这个问题,我们测试了现有的异构体特异性
和广谱ALDH抑制剂对培养的细胞,发现没有一个是非常有效的调节细胞,
生存此外,我们预测,由于重叠,需要一种广谱抑制剂。
ALDH家族成员的功能。这些观察结果提供了开发无毒广泛的
谱ALDH抑制剂,其将杀死ALDH+ CSC以防止复发性抗性疾病,并改善
黑色素瘤的免疫治疗因此,中心假设是可以开发无毒ALDH抑制剂
减少由ALDH+ CSC介导的复发性抗性疾病的发展,并提高
现有的免疫疗法通过减少免疫抑制。初步数据显示,
无毒ALDH抑制剂建立在靛红天然产物的骨架上。该药剂可消除CSC,
高ALDH活性,防止ALDH+细胞的增加,这在传统药物治疗中是常见的。最后,
该抑制剂改善了抗PD 1免疫疗法在同基因小鼠黑色素瘤模型中的临床前功效
这种方法本身并不有效。根据这些支持假设的初步数据,
提出了具体目标。首先,确定无毒广谱ALDH抑制剂
消除了在用传统化疗治疗时扩大的黑色素瘤ALDH+ CSC群体。
此外,确定其与传统化疗联合使用时预防复发性耐药的效力
疾病发展。这将通过从细胞系中分离ALDH+和ALDH-细胞群来实现,
患者来源的(PDX)肿瘤和确定抑制剂功效以预防复发性耐药疾病
当与当前临床相关化疗联合使用时,最后
将鉴定通过药剂组合抑制抗性的机理基础。第二,确定
无毒广谱ALDH抑制剂对肿瘤中免疫调节和效应细胞的功效
单独使用和与抗PD 1抗体免疫疗法联合使用时,可以改善微环境。特异性靶向
将测试ALDH在黑色素瘤肿瘤细胞和宿主细胞中的治疗功效。机制导致
通过确定抑制剂和抗体组合的影响,
对肿瘤内免疫细胞组成和功能的影响,评估免疫细胞中的相对ALDH水平,
细胞群,并使用瞬时和遗传方法来靶向调节免疫细胞。这些
重要的发现将证明靶向癌症中的ALDH酶用于调节癌症的有效性。
抗性和免疫细胞功能,提供临床转化所需的临床前验证。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHANTU G AMIN其他文献
SHANTU G AMIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHANTU G AMIN', 18)}}的其他基金
Targeting Aldehyde Dehydrogenase for Cancer Prevention
以醛脱氢酶为靶点预防癌症
- 批准号:
10327368 - 财政年份:2020
- 资助金额:
$ 60.05万 - 项目类别:
Targeting Aldehyde Dehydrogenase for Cancer Prevention
以醛脱氢酶为靶点预防癌症
- 批准号:
9973328 - 财政年份:2020
- 资助金额:
$ 60.05万 - 项目类别:
相似海外基金
The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
- 批准号:
EP/Z000920/1 - 财政年份:2025
- 资助金额:
$ 60.05万 - 项目类别:
Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
- 批准号:
FT230100276 - 财政年份:2024
- 资助金额:
$ 60.05万 - 项目类别:
ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
- 批准号:
MR/X024261/1 - 财政年份:2024
- 资助金额:
$ 60.05万 - 项目类别:
Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
- 批准号:
DE240100388 - 财政年份:2024
- 资助金额:
$ 60.05万 - 项目类别:
Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
- 批准号:
2889694 - 财政年份:2023
- 资助金额:
$ 60.05万 - 项目类别:
Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
- 批准号:
2842926 - 财政年份:2023
- 资助金额:
$ 60.05万 - 项目类别:
Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
- 批准号:
NC/X001644/1 - 财政年份:2023
- 资助金额:
$ 60.05万 - 项目类别:
Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
- 批准号:
2337595 - 财政年份:2023
- 资助金额:
$ 60.05万 - 项目类别:
Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
- 批准号:
2232190 - 财政年份:2023
- 资助金额:
$ 60.05万 - 项目类别:
Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
- 批准号:
23K17514 - 财政年份:2023
- 资助金额:
$ 60.05万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)